Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.
Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...
Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for ...
12d
First Oral Pill For Adults With Thalassemia Anaemia Gets Approval, Experts Hail It As Game Changer
The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks ...
Agios Pharmaceuticals AGIO announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia. With this approval, Aqvesme becomes the only FDA ...
India Today on MSN
US approves first pill for thalassemia anemia: What this means for India
The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...
Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against ...
CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback